Literature DB >> 12415307

Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance.

Matthias J Reddehase1.   

Abstract

CD8+ T cells are the main effector cells for the immune control of cytomegaloviruses. To subvert this control, human and mouse cytomegaloviruses each encode a set of immune-evasion proteins, referred to here as immunoevasins, which interfere specifically with the MHC class I pathway of antigen processing and presentation. Although the concerted action of immunoevasins prevents the presentation of certain viral peptides, other viral peptides escape this blockade conditionally or constitutively and thereby provide the molecular basis of immune surveillance by CD8+ T cells. The definition of viral antigenic peptides that are presented despite the presence of immunoevasins adds a further dimension to the prediction of protective epitopes for use in vaccines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12415307     DOI: 10.1038/nri932

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  132 in total

1.  Cross-reactivity of HLA-B*1801-restricted T-lymphocyte clones with target cells expressing variants of the human cytomegalovirus 72kDa-IE1 protein.

Authors:  Virginie Prod'homme; Christelle Retière; Ralitza Valtcheva; Marc Bonneville; Marie-Martine Hallet
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

2.  HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes.

Authors:  Gabriella Pietra; Chiara Romagnani; Paola Mazzarino; Michela Falco; Enrico Millo; Alessandro Moretta; Lorenzo Moretta; Maria Cristina Mingari
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

Review 3.  Cross-priming in health and disease.

Authors:  Christian Kurts; Bruce W S Robinson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-06       Impact factor: 53.106

4.  B7-mediated costimulation of CD4 T cells constrains cytomegalovirus persistence.

Authors:  Ramon Arens; Andrea Loewendorf; Min J Her; Kirsten Schneider-Ohrum; Geoffrey R Shellam; Edith Janssen; Carl F Ware; Stephen P Schoenberger; Chris A Benedict
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

5.  Persistent viral infection in humans can drive high frequency low-affinity T-cell expansions.

Authors:  Naeem Khan; Mark Cobbold; Joanne Cummerson; Paul A H Moss
Journal:  Immunology       Date:  2010-08-16       Impact factor: 7.397

6.  Cytomegalovirus encodes a positive regulator of antigen presentation.

Authors:  Rafaela Holtappels; Dorothea Gillert-Marien; Doris Thomas; Jürgen Podlech; Petra Deegen; Sylvia Herter; Silke A Oehrlein-Karpi; Dennis Strand; Markus Wagner; Matthias J Reddehase
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

7.  Dynamics of killer T cell inflation in viral infections.

Authors:  Dominik Wodarz; Sophie Sierro; Paul Klenerman
Journal:  J R Soc Interface       Date:  2007-06-22       Impact factor: 4.118

8.  Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties.

Authors:  Irena Slavuljica; Andreas Busche; Marina Babić; Maja Mitrović; Iva Gašparović; Durđica Cekinović; Elitza Markova Car; Ester Pernjak Pugel; Ana Ciković; Vanda Juranić Lisnić; William J Britt; Ulrich Koszinowski; Martin Messerle; Astrid Krmpotić; Stipan Jonjić
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

9.  Cytomegalovirus infection in childhood-onset systemic lupus erythematosus.

Authors:  Evelyn V Rozenblyum; Upton D Allen; Earl D Silverman; Deborah M Levy
Journal:  Int J Clin Rheumtol       Date:  2013-02

10.  Immune evasion proteins of murine cytomegalovirus preferentially affect cell surface display of recently generated peptide presentation complexes.

Authors:  Niels A W Lemmermann; Kerstin Gergely; Verena Böhm; Petra Deegen; Torsten Däubner; Matthias J Reddehase
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.